Keywords: BDNF; brain-derived neurotrophic factor; CFA; caudal forelimb area; ChR2; channelrhodopsin-2; CIMT; constraint-induced movement therapy; CSPGs; chondroitin sulfate proteoglycans; iTBS; intermittent theta burst stimulation; MSCs; mesenchymal stem cells; PN